Skip to content

Glaukos GKOS Enterprise value

Enterprise value at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$622.06B+50.5%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$81.42B+18.1%
AbbVie logo
AbbVieABBV
$460.96B+24.7%
Boston Scientific logo
Boston ScientificBSX
$141.04B-1.0%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
$15.19B-20.2%
Exelixis logo
ExelixisEXEL
$11.24B+9.5%

Other financials

Income statement

See full
Revenue$150.6M+41.2%
Gross profit$117.2M+42.4%
Operating income-$19.9M+4.0%
Net income-$19.8M-9.0%
EPS (diluted)-$0.34-6.3%

Balance sheet

See full
Cash & equivalents$104.2M-8.8%
Total debt$105.9M-1.7%
Total equity$670.9M-12.2%
Total assets$893.3M-7.5%

Cash flow

See full
Operating cash flow-$12.5M+32.4%
CapEx$4.0M+104%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$7.68B+12.3%
P/S13.9×-3.0×

Profitability

See full
Gross margin78.1%+2.3pp
Operating margin-36.1%+24.3pp
Net margin-34.3%+4.8pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26.4%+11.1pp
Debt / equity0.2×0.0×
Current ratio5.4×-1.1×

Where this comes from

Calculated from Glaukos’s reported figures.

The official record: Glaukos’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Glaukos's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Glaukos's enterprise value?
Glaukos (GKOS) reported enterprise value of $6.25B in Q1 2026.
How has Glaukos's enterprise value changed year-over-year?
Glaukos's enterprise value increased by 12.5% year-over-year, from $5.56B to $6.25B.
What is the long-term trend for Glaukos's enterprise value?
Over 5 years (2020 to 2025), Glaukos's enterprise value has grown at a 13.1% compound annual growth rate (CAGR), from $3.51B to $6.5B.
What does enterprise value mean?
What it would cost to buy the entire business, debt included and cash netted out.
How do you interpret enterprise value?
The capital-structure-neutral valuation base — used in EV/EBITDA and EV/Sales to compare companies with different leverage on a like-for-like footing.
How does enterprise value compare across companies?
Comparable across non-financial companies via the EV multiples it feeds; not used for banks and insurers.